The use of flunarizine in pediatric epilepsy.

Abstract

Using the same technique as Declerk's and Wauquier's, we added flunarizine to standard therapy in 14 patients, 7 of whom were treated with the sequence flunarizine-placebo and 7 with the sequence placebo-flunarizine. Treatment averaged between 75 and 85 days, with medication administered in a single dose (orally, in drops), 5-10 mg/day. The patients comprised 7 males and 7 females, from 13 to 17 years with the following diagnoses: epileptic encephalopathy 6 cases, grand mal, myoclonic epilepsy, multifocal epilepsy, epilepsy with polymorphic seizures, 2 cases each. Age, sex and disease were distributed equally in both sequences. During treatment with flunarizine we observed the following: 7 cases--no effect on number or severity of seizures; 2 cases--moderate results; 5 cases--good results.

• Authors: G B Cavazzuti, V Galli, A Benatti
• Journal: Functional neurology (Funct Neurol) 1986 Oct-Dec Vol. 1 Issue 4 Pg. 551-4 ISSN: 0393-5264 [Print] Italy
• PMID: 3609882 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)

Chemical References

• Anticonvulsants
• Flunarizine

Topics

• Adolescent
• Anticonvulsants (therapeutic use)
• Child
• Child, Preschool
• Double-Blind Method
• Drug Therapy, Combination
• Epilepsy (drug therapy)
• Female
• Flunarizine (adverse effects, therapeutic use)
• Humans
• Male